摘要
目的探讨5-HT2c受体基因-759C/T、-697G/C多态性与非典型抗精神病药物治疗首发精神分裂症患者疗效的关系。方法179例首发精神分裂症患者接受利培酮或氯氮平治疗8周,以PANSS量表评定患者的症状改善,以聚合酶链式反应(PCR)扩增及限制性片段长度多态性(RFLP)技术,检测5-HT2C受体基因-759C/T及-697G/C多态性。结果女性患者携带-759C等位基因的总疗效较-759T好,C/C基因型的阴性症状改善及总疗效优于C/T及T/T基因型,没有发现男性组和女性组697C/G各基因型与疗效存在关联。结论5-HT2c受体基因-759C/T基因多态性可能与非典型抗精神病药的疗效相关,C/C基因型和等位基因C可能是总体疗效好和阴性症状疗效好的预测因子。5-HT2c受体基因-697G/C基因多态性可能与非典型抗精神病药的疗效无关。
Objective To investigate the association of the 5 - HT2c receptor gene-759C/T and-697C/G polymorphism with therapeutic response of atypical antipsychotics in first-episode schizophrenic patients. Methods 179 first-episode schizophrenic patients were treated by risperidone and clozapine for 8 weeks. The severity of symptoms and the therapeutic responses of drugs SS) . The genotypes and allele frequencies of 5 were evaluaded by the positive and negative symptom scale (PAN- - HT2c receptor genes were assayed by polymerase chain reaction (PCR) amplification and Restriction Fragment Length Polymorphism (RFLP) technique. Results The therapeu- tic effect of female patients with -759C allele are better than that with -759T allele. A significant association be- tween total PANSS and negative symptoms scores reduction of female patients with C/C genetype was apparent. The 5 - HT2o receptor-697C/G genetypes is not significantly associated with the improvement of the positive symp- tom and negative symptom either in male patient group or in female patient group. Conclusions 5 - HT2c receptor gene-759C/T polymorphism may associate with clinical response to antipsychotics on first-episode schizophrenia. C/C genotype and C allele is likely to be a predictive factor of antipsychotics efficacy. 5 - HT2c receptor gene 697C/G polymorphism may not associate with clinical response.
出处
《国际精神病学杂志》
2009年第4期196-199,共4页
Journal Of International Psychiatry